Terenius et al., 1972 - Google Patents
Aspects on the mode of action of antiestrogens and antiprogestogensTerenius et al., 1972
- Document ID
- 7751244358199093454
- Author
- Terenius L
- Ljungkvist I
- Publication year
- Publication venue
- Gynecologic and Obstetric Investigation
External Links
Snippet
Most so-called antiestrogens are 'estrogenic'in the mouse uterine growth test and in the Allen-Doisy test (in mice or rats). With regard to their uterotrophic effects, they were classified as giving normal (cis-and trans-clomiphene, ICI-46,474 and U-11,555 A); impeded (estriol …
- 230000001833 anti-estrogenic 0 title abstract description 42
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propanolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epihephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Santen et al. | Endocrine treatment of breast cancer in women | |
Mauvais-Jarvis et al. | Antiestrogen action of progesterone in breast tissue | |
Taraborrelli | Physiology, production and action of progesterone | |
Santen et al. | Use of aromatase inhibitors in breast carcinoma. | |
DE69022722T2 (en) | COMBINATION THERAPY FOR TREATING ESTROGEN SENSITIVE DISEASES. | |
Sitruk-Ware | New progestogens: a review of their effects in perimenopausal and postmenopausal women | |
Terenius et al. | Aspects on the mode of action of antiestrogens and antiprogestogens | |
Der Schoot et al. | Effects of the progesterone antagonist RU486 on ovarian activity in the rat | |
Robbins et al. | Mifepristone: clinical pharmacology | |
Tsai et al. | Antagonism of development and growth of 7, 12-dimethylbenz (a) anthracene-induced rat mammary tumors by the antiestrogen U 23,469 and effects on estrogen and progesterone receptors | |
Huggins et al. | The depression of growth of the uterus, adrenals, and ovaries by fluorinated steroids in the pregnane series | |
Clark et al. | The agonistic and antagonistic actions of estriol | |
Schumacher et al. | Neurosteroids: synthesis and functions in the central and peripheral nervous systems | |
Perusquía | Nongenomic action of steroids in myometrial contractility | |
Aumüller et al. | Phenotypic modulation of the canine prostate after long‐term treatment with androgens and estrogens | |
CALLANTINE | Nonsteroidal estrogen antagonists | |
Burghardt et al. | Gap junction modulation in rat uterus. III. Structure-activity relationships of estrogen receptor-binding ligands on myometrial and serosal cells | |
Mauvais-Jarvis et al. | Antiestrogen action of progesterone in breast tissue | |
Götze et al. | Anti-oestrogenic effects of tamoxifen on mammary gland and hypophysis in female rats | |
Schatz et al. | In Vitro Inhibition with Antiestrogens of Estradiol Effects on Prostaglandin F2 α Production by Human Endometrium and Endometrial Epithelial Cells | |
Baulieu | Aspects of steroid hormone-target cell interactions | |
Burghardt et al. | Gap junction modulation in rat uterus. II. Effects of antiestrogens on myometrial and serosal cells | |
Sengupta et al. | Effect of an estrogen antagonist on development of blastocysts and implantation in the hamster | |
Spicer et al. | Effects of 2-hydroxyestradiol on the number of granulosa cell β-adrenergic receptors | |
JP2004511523A (en) | Use of antiprogestin to induce apoptosis in cells |